ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

 

ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy
M

Loss of Function of the SETD2 Tumor Suppressor is a Recurrent Event in Advanced-phase Chronic Myeloid Leukemia, is Due to Post-translational Mechanisms and Fosters Genetic Instability

By ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy FEATURING Manuela Mancini
By ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy FEATURING Manuela Mancini
0 views
January 2, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi
Scientific Session 3: The Microenvironment and Mechanisms of Transformation
11:41
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

Loss of Function of the SETD2 Tumor Suppressor is a Recurrent Event …

Feat. M. Mancini
17:28
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

CML Hematopoietic Stem Cells Expressing IL-1RAP May be Targets of Ch…

Feat. C. Ferrand